GNRH1 and ovarian hyperstimulation syndrome: In ongoing UTx trials, both long protocols with GnRH agonist and hCG trigger, and short protocols with GnRH antagonists and GnRH-agonist trigger, have been used; however, the majority uses the latter to minimize risk of ovarian hyperstimulation syndrome, which has occurred in one UTx patient (Brännström et al., 2022a).